Adze Biotechnology is pioneering the development of a novel platform of oncolytic immunotherapies aimed at treating solid tumors and enhancing anti-tumor immunity in patients. Central to their approach is a proprietary oncolytic viral backbone that facilitates systemic delivery of therapeutic payloads directly to tumors, including immune-modulating agents and checkpoint inhibitors. This innovative technology not only allows for the direct killing of cancer cells through cell lysis but also promotes the release of tumor neoantigens, which help the immune system recognize and attack the cancer. By transforming "cold" tumors into "hot" ones, Adze's therapies aim to improve T cell infiltration and function within the tumor microenvironment, addressing significant challenges faced by traditional checkpoint inhibitors.

The company is focused on advancing a diverse pipeline of drug candidates that leverage their oncolytic platform, which has shown promise in delivering enhanced anti-PD-1 payloads and clinically validated immune-stimulatory proteins. Adze Biotechnology's strategic vision includes building partnerships with major pharmaceutical companies to maximize the potential of their therapies and expand their intellectual property portfolio, particularly in the context of a growing market for checkpoint inhibitors. With a commitment to addressing unmet medical needs in oncology, Adze is positioned to make significant contributions to the field of cancer immunotherapy.

United States

Adze Biotechnology is a biotechnology company that develops a platform of immunotherapies to treat solid tumors and enhance anti-tumor immunity.

Adze Biotechnology

Company Details